Laracy Justin C, Verna Elizabeth C, Pereira Marcus R
Department of Medicine, Division of Infectious Disease, Columbia University College of Physicians & Surgeons, 622 W 168th St PH 876 W, New York, NY 10032 USA.
Department of Medicine, Division of Digestive & Liver Diseases, Columbia University College of Physicians & Surgeons, New York, NY USA.
Curr Transplant Rep. 2020;7(4):355-365. doi: 10.1007/s40472-020-00304-z. Epub 2020 Oct 21.
To evaluate the critical studies published so far on the most promising antiviral therapies for COVID-19, with particular emphasis on any solid organ transplant-specific information.
Although the literature is increasing exponentially, most clinical trials have been preliminary, thus lacking robust evidence to support many of the drugs discussed here. The main exception is remdesivir, for which several trials have been published supporting its use for patients with severe COVID-19. No solid organ transplant-specific data on remdesivir or other antiviral therapies have been published so far.
While further studies are urgently needed, in particular those specific to solid organ transplant recipients, the evidence so far only supports the use of remdesivir for patients with severe COVID-19.
评估迄今为止发表的关于最有前景的COVID-19抗病毒疗法的关键研究，特别强调任何实体器官移植特异性信息。
尽管文献数量呈指数级增长，但大多数临床试验都是初步的，因此缺乏有力证据支持这里讨论的许多药物。主要例外是瑞德西韦，已经发表了几项试验支持其用于重症COVID-19患者。迄今为止，尚未发表关于瑞德西韦或其他抗病毒疗法的实体器官移植特异性数据。
虽然迫切需要进一步研究，特别是针对实体器官移植受者的研究，但迄今为止的证据仅支持将瑞德西韦用于重症COVID-19患者。
